{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:23:43Z","timestamp":1793467423332,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","award":["PPG-2023-0000000139"],"award-info":[{"award-number":["PPG-2023-0000000139"]}],"id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","award":["GSA-2022-0000000100"],"award-info":[{"award-number":["GSA-2022-0000000100"]}],"id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CIHR Doctoral Vanier Canada Graduate Scholarship","award":["CGV-186893"],"award-info":[{"award-number":["CGV-186893"]}]},{"name":"CIHR Canadian Graduate Scholarship Doctoral Research Award","award":["514557"],"award-info":[{"award-number":["514557"]}]},{"name":"Ontario Graduate Scholarship"},{"name":"New Frontiers in Research Fund, Canada","award":["NFRFT-2022-00051"],"award-info":[{"award-number":["NFRFT-2022-00051"]}]},{"name":"New Frontiers in Research Fund, Canada","award":["NFRFT-2022-00051"],"award-info":[{"award-number":["NFRFT-2022-00051"]}]},{"name":"New Frontiers in Research Fund, Canada","award":["NFRFT-2022-00051"],"award-info":[{"award-number":["NFRFT-2022-00051"]}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-169042"],"award-info":[{"award-number":["PJT-169042"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-195804"],"award-info":[{"award-number":["PJT-195804"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["Tier 2 in protein misfolding disorders"],"award-info":[{"award-number":["Tier 2 in protein misfolding disorders"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["Tier 1 in Parkinson's Disease"],"award-info":[{"award-number":["Tier 1 in Parkinson's Disease"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-025-02151-4","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:36:54Z","timestamp":1762346214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["\u03b1-Synuclein purification significantly impacts seed amplification assay performance and consistency"],"prefix":"10.1186","volume":"13","author":[{"given":"Zaid A. M.","family":"Al-Azzawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R. G.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Situ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Shlaifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ingelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley T.","family":"Hyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Trempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Durcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel C.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Fon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2151_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12020324","author":"M Al-Azzani","year":"2022","unstructured":"Al-Azzani M, Konig A, Outeiro TF (2022) Production of recombinant Alpha-synuclein: still no standardized protocol in sight. Biomolecules. https:\/\/doi.org\/10.3390\/biom12020324","journal-title":"Biomolecules"},{"key":"2151_CR2","doi-asserted-by":"publisher","first-page":"7606","DOI":"10.1039\/c4cp05563b","volume":"17","author":"P Arosio","year":"2015","unstructured":"Arosio P, Knowles TP, Linse S (2015) On the lag phase in amyloid fibril formation. Phys Chem Chem Phys 17:7606\u20137618. https:\/\/doi.org\/10.1039\/c4cp05563b","journal-title":"Phys Chem Chem Phys"},{"key":"2151_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13024-021-00491-y","volume":"16","author":"C Bargar","year":"2021","unstructured":"Bargar C, De Luca CMG, Devigili G, Elia AE, Cilia R, Portaleone SM et al (2021) Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Mol Neurodegener 16:82. https:\/\/doi.org\/10.1186\/s13024-021-00491-y","journal-title":"Mol Neurodegener"},{"key":"2151_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","volume":"9","author":"C Bargar","year":"2021","unstructured":"Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ et al (2021) Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9:62. https:\/\/doi.org\/10.1186\/s40478-021-01175-w","journal-title":"Acta Neuropathol Commun"},{"key":"2151_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels T, Choi JG, Selkoe DJ (2011) Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477:107\u2013110. https:\/\/doi.org\/10.1038\/nature10324","journal-title":"Nature"},{"key":"2151_CR6","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1038\/s41593-024-01775-4","volume":"27","author":"A Bayati","year":"2024","unstructured":"Bayati A, Ayoubi R, Aguila A, Zorca CE, Deyab G, Han C et al (2024) Modeling Parkinson\u2019s disease pathology in human dopaminergic neurons by sequential exposure to \u03b1-synuclein fibrils and proinflammatory cytokines. Nat Neurosci 27:2401\u20132416. https:\/\/doi.org\/10.1038\/s41593-024-01775-4","journal-title":"Nat Neurosci"},{"key":"2151_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/WNL.0000000000200878","volume":"99","author":"G Bellomo","year":"2022","unstructured":"Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L (2022) Alpha-synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology 99:195\u2013205. https:\/\/doi.org\/10.1212\/WNL.0000000000200878","journal-title":"Neurology"},{"key":"2151_CR8","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.52586\/5010","volume":"26","author":"G Bellomo","year":"2021","unstructured":"Bellomo G, Paciotti S, Gatticchi L, Rizzo D, Paoletti FP, Fragai M et al (2021) Seed amplification assays for diagnosing synucleinopathies: the issue of influencing factors. Front Biosci (Landmark Ed) 26:1075\u20131088. https:\/\/doi.org\/10.52586\/5010","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2151_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00401-023-02663-0","volume":"147","author":"GM Bentivenga","year":"2024","unstructured":"Bentivenga GM, Mammana A, Baiardi S, Rossi M, Ticca A, Magliocchetti F et al (2024) Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol 147:18. https:\/\/doi.org\/10.1007\/s00401-023-02663-0","journal-title":"Acta Neuropathol"},{"key":"2151_CR10","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/mds.29923","volume":"39","author":"AM Bernhardt","year":"2024","unstructured":"Bernhardt AM, Nemati M, Boros FA, Hopfner F, Levin J, Mollenhauer B et al (2024) Alpha-synuclein seed amplification assays from blood-based extracellular vesicles in Parkinson\u2019s disease: an evaluation of the evidence. Mov Disord 39:1269\u20131271. https:\/\/doi.org\/10.1002\/mds.29923","journal-title":"Mov Disord"},{"key":"2151_CR11","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/acn3.50897","volume":"6","author":"M Bongianni","year":"2019","unstructured":"Bongianni M, Ladogana A, Capaldi S, Klotz S, Baiardi S, Cagnin A et al (2019) Alpha-synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann Clin Transl Neurol 6:2120\u20132126. https:\/\/doi.org\/10.1002\/acn3.50897","journal-title":"Ann Clin Transl Neurol"},{"key":"2151_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s40478-023-01653-3","volume":"11","author":"S Brauer","year":"2023","unstructured":"Brauer S, Rossi M, Sajapin J, Henle T, Gasser T, Parchi P et al (2023) Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders. Acta Neuropathol Commun 11:162. https:\/\/doi.org\/10.1186\/s40478-023-01653-3","journal-title":"Acta Neuropathol Commun"},{"key":"2151_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70165","volume":"32","author":"S Brauer","year":"2025","unstructured":"Brauer S, Weber M, Deuschle C, Julia K, Concha-Marambio L, Bernhardt AM et al (2025) High agreement across laboratories between different Alpha-synuclein seed amplification protocols. Eur J Neurol 32:e70165. https:\/\/doi.org\/10.1111\/ene.70165","journal-title":"Eur J Neurol"},{"key":"2151_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41531-023-00627-5","volume":"10","author":"K Brockmann","year":"2024","unstructured":"Brockmann K, Lerche S, Baiardi S, Rossi M, Wurster I, Quadalti C et al (2024) CSF alpha-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson\u2019s disease. NPJ Parkinsons Dis 10:24. https:\/\/doi.org\/10.1038\/s41531-023-00627-5","journal-title":"NPJ Parkinsons Dis"},{"key":"2151_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40478-021-01276-6","volume":"9","author":"K Brockmann","year":"2021","unstructured":"Brockmann K, Quadalti C, Lerche S, Rossi M, Wurster I, Baiardi S et al (2021) Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9:175. https:\/\/doi.org\/10.1186\/s40478-021-01276-6","journal-title":"Acta Neuropathol Commun"},{"key":"2151_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40478-025-02034-8","volume":"13","author":"R Bsoul","year":"2025","unstructured":"Bsoul R, McWilliam OH, Waldemar G, Hasselbalch SG, Simonsen AH, von Buchwald C et al (2025) Accurate detection of pathologic alpha-synuclein in CSF, skin, olfactory mucosa, and urine with a uniform seeding amplification assay. Acta Neuropathol Commun 13:113. https:\/\/doi.org\/10.1186\/s40478-025-02034-8","journal-title":"Acta Neuropathol Commun"},{"key":"2151_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0326568","volume":"20","author":"R Bsoul","year":"2025","unstructured":"Bsoul R, Simonsen AH, Frederiksen KS, Svenstrup K, Bech S, Salvesen L et al (2025) Seeding amplification assay with universal control fluid: standardized detection of alpha-synucleinopathies. PLoS ONE 20:e0326568. https:\/\/doi.org\/10.1371\/journal.pone.0326568","journal-title":"PLoS ONE"},{"key":"2151_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ana.25446","volume":"85","author":"N Candelise","year":"2019","unstructured":"Candelise N, Schmitz M, Llorens F, Villar-Pique A, Cramm M, Thom T et al (2019) Seeding variability of different alpha synuclein strains in synucleinopathies. Ann Neurol 85:691\u2013703. https:\/\/doi.org\/10.1002\/ana.25446","journal-title":"Ann Neurol"},{"key":"2151_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jmb.2004.09.096","volume":"344","author":"D Cherny","year":"2004","unstructured":"Cherny D, Hoyer W, Subramaniam V, Jovin TM (2004) Double-stranded DNA stimulates the fibrillation of alpha-synuclein in vitro and is associated with the mature fibrils: an electron microscopy study. J Mol Biol 344:929\u2013938. https:\/\/doi.org\/10.1016\/j.jmb.2004.09.096","journal-title":"J Mol Biol"},{"key":"2151_CR20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","volume":"18","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Pritzkow S, Shahnawaz M, Farris CM, Soto C (2023) Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat Protoc 18:1179\u20131196. https:\/\/doi.org\/10.1038\/s41596-022-00787-3","journal-title":"Nat Protoc"},{"key":"2151_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210279","volume":"104","author":"DG Coughlin","year":"2025","unstructured":"Coughlin DG, Shifflett B, Farris CM, Ma Y, Galasko D, Edland SD et al (2025) Alpha-Synuclein seed amplification assay amplification parameters and the risk of progression in prodromal Parkinson disease. Neurology 104:e210279. https:\/\/doi.org\/10.1212\/WNL.0000000000210279","journal-title":"Neurology"},{"key":"2151_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40035-019-0164-x","volume":"8","author":"CMG De Luca","year":"2019","unstructured":"De Luca CMG, Elia AE, Portaleone SM, Cazzaniga FA, Rossi M, Bistaffa E et al (2019) Efficient RT-QuIC seeding activity for alpha-synuclein in olfactory mucosa samples of patients with Parkinson\u2019s disease and multiple system atrophy. Transl Neurodegener 8:24. https:\/\/doi.org\/10.1186\/s40035-019-0164-x","journal-title":"Transl Neurodegener"},{"key":"2151_CR23","unstructured":"Del Cid Pellitero E, Shlaifer R, Luo W, Krahn A, Nguyen-Renou E, Manecka D-L et al (2019) Quality control characterization of \u03b1-synuclein preformed fibrils (PFFs). City"},{"key":"2151_CR24","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1038\/s41467-024-46832-5","volume":"15","author":"DD Dhavale","year":"2024","unstructured":"Dhavale DD, Barclay AM, Borcik CG, Basore K, Berthold DA, Gordon IR et al (2024) Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue. Nat Commun 15:2750. https:\/\/doi.org\/10.1038\/s41467-024-46832-5","journal-title":"Nat Commun"},{"key":"2151_CR25","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S et al (2016) Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 3:812\u2013818. https:\/\/doi.org\/10.1002\/acn3.338","journal-title":"Ann Clin Transl Neurol"},{"key":"2151_CR26","doi-asserted-by":"publisher","first-page":"15345","DOI":"10.1074\/jbc.M111.318949","volume":"287","author":"B Fauvet","year":"2012","unstructured":"Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT et al (2012) Alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287:15345\u201315364. https:\/\/doi.org\/10.1074\/jbc.M111.318949","journal-title":"J Biol Chem"},{"key":"2151_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/cells12071083","volume":"12","author":"B Feller","year":"2023","unstructured":"Feller B, Fallon A, Luo W, Nguyen PT, Shlaifer I, Lee AK et al (2023) \u03b1-Synuclein preformed fibrils bind to \u03b2-neurexins and impair \u03b2-neurexin-mediated presynaptic organization. Cells 12:1083","journal-title":"Cells"},{"key":"2151_CR28","doi-asserted-by":"publisher","DOI":"10.1017\/S0033583516000172","volume":"50","author":"R Gaspar","year":"2017","unstructured":"Gaspar R, Meisl G, Buell AK, Young L, Kaminski CF, Knowles TPJ et al (2017) Secondary nucleation of monomers on fibril surface dominates alpha-synuclein aggregation and provides autocatalytic amyloid amplification. Q Rev Biophys 50:e6. https:\/\/doi.org\/10.1017\/S0033583516000172","journal-title":"Q Rev Biophys"},{"key":"2151_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ymeth.2010.12.008","volume":"53","author":"L Giehm","year":"2011","unstructured":"Giehm L, Lorenzen N, Otzen DE (2011) Assays for alpha-synuclein aggregation. Methods 53:295\u2013305. https:\/\/doi.org\/10.1016\/j.ymeth.2010.12.008","journal-title":"Methods"},{"key":"2151_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbapap.2004.10.008","volume":"1703","author":"CB Glaser","year":"2005","unstructured":"Glaser CB, Yamin G, Uversky VN, Fink AL (2005) Methionine oxidation, alpha-synuclein and Parkinson\u2019s disease. Biochim Biophys Acta 1703:157\u2013169. https:\/\/doi.org\/10.1016\/j.bbapap.2004.10.008","journal-title":"Biochim Biophys Acta"},{"key":"2151_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman BR, Orru CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B et al (2018) Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. Acta Neuropathol Commun 6:7. https:\/\/doi.org\/10.1186\/s40478-018-0508-2","journal-title":"Acta Neuropathol Commun"},{"key":"2151_CR32","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2741\/3628","volume":"15","author":"ML Hegde","year":"2010","unstructured":"Hegde ML, Vasudevaraju P, Rao KJ (2010) DNA induced folding\/fibrillation of alpha-synuclein: new insights in Parkinson\u2019s disease. Front Biosci (Landmark Ed) 15:418\u2013436. https:\/\/doi.org\/10.2741\/3628","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2151_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W et al (2024) A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol 23:191\u2013204. https:\/\/doi.org\/10.1016\/S1474-4422(23)00404-0","journal-title":"Lancet Neurol"},{"key":"2151_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pep.2005.02.014","volume":"42","author":"C Huang","year":"2005","unstructured":"Huang C, Ren G, Zhou H, Wang CC (2005) A new method for purification of recombinant human alpha-synuclein in Escherichia coli. Protein Expr Purif 42:173\u2013177. https:\/\/doi.org\/10.1016\/j.pep.2005.02.014","journal-title":"Protein Expr Purif"},{"key":"2151_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","volume":"20","author":"A Iranzo","year":"2021","unstructured":"Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I et al (2021) Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol 20:203\u2013212. https:\/\/doi.org\/10.1016\/S1474-4422(20)30449-X","journal-title":"Lancet Neurol"},{"key":"2151_CR36","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mds.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang UJ, Boehme AK, Fairfoul G, Shahnawaz M, Ma TC, Hutten SJ et al (2019) Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease. Mov Disord 34:536\u2013544. https:\/\/doi.org\/10.1002\/mds.27646","journal-title":"Mov Disord"},{"key":"2151_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt7195","volume":"11","author":"HA Lashuel","year":"2025","unstructured":"Lashuel HA, Surmeier DJ, Simuni T, Merchant K, Caughey B, Soto C et al (2025) Alpha-synuclein seed amplification assays: data sharing, standardization needed for clinical use. Sci Adv 11:eadt7195. https:\/\/doi.org\/10.1126\/sciadv.adt7195","journal-title":"Sci Adv"},{"key":"2151_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41593-019-0541-x","volume":"23","author":"A Lau","year":"2020","unstructured":"Lau A, So RWL, Lau HHC, Sang JC, Ruiz-Riquelme A, Fleck SC et al (2020) Alpha-Synuclein strains target distinct brain regions and cell types. Nat Neurosci 23:21\u201331. https:\/\/doi.org\/10.1038\/s41593-019-0541-x","journal-title":"Nat Neurosci"},{"key":"2151_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40478-023-01570-5","volume":"11","author":"HHC Lau","year":"2023","unstructured":"Lau HHC, Martinez-Valbuena I, So RWL, Mehra S, Silver NRG, Mao A et al (2023) The G51D SNCA mutation generates a slowly progressive alpha-synuclein strain in early-onset Parkinson\u2019s disease. Acta Neuropathol Commun 11:72. https:\/\/doi.org\/10.1186\/s40478-023-01570-5","journal-title":"Acta Neuropathol Commun"},{"key":"2151_CR40","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/2211-5463.13110","volume":"11","author":"S Lovestam","year":"2021","unstructured":"Lovestam S, Schweighauser M, Matsubara T, Murayama S, Tomita T, Ando T et al (2021) Seeded assembly in vitro does not replicate the structures of alpha-synuclein filaments from multiple system atrophy. FEBS Open Bio 11:999\u20131013. https:\/\/doi.org\/10.1002\/2211-5463.13110","journal-title":"FEBS Open Bio"},{"key":"2151_CR41","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1474-4422(24)00395-8","volume":"23","author":"Y Ma","year":"2024","unstructured":"Ma Y, Farris CM, Weber S, Schade S, Nguyen H, Perez-Soriano A et al (2024) Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study. Lancet Neurol 23:1225\u20131237. https:\/\/doi.org\/10.1016\/S1474-4422(24)00395-8","journal-title":"Lancet Neurol"},{"key":"2151_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.737195","volume":"12","author":"K Malfertheiner","year":"2021","unstructured":"Malfertheiner K, Stefanova N, Heras-Garvin A (2021) The concept of alpha-synuclein strains and how different conformations may explain distinct neurodegenerative disorders. Front Neurol 12:737195. https:\/\/doi.org\/10.3389\/fneur.2021.737195","journal-title":"Front Neurol"},{"key":"2151_CR43","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/mds.28651","volume":"36","author":"A Mammana","year":"2021","unstructured":"Mammana A, Baiardi S, Quadalti C, Rossi M, Donadio V, Capellari S et al (2021) Rt-quic detection of pathological alpha-Synuclein in skin punches of patients with Lewy body disease. Mov Disord 36:2173\u20132177. https:\/\/doi.org\/10.1002\/mds.28651","journal-title":"Mov Disord"},{"key":"2151_CR44","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1515\/cclm-2023-1472","volume":"62","author":"A Mammana","year":"2024","unstructured":"Mammana A, Baiardi S, Rossi M, Quadalti C, Ticca A, Magliocchetti F et al (2024) Improving protocols for alpha-synuclein seed amplification assays: analysis of preanalytical and analytical variables and identification of candidate parameters for seed quantification. Clin Chem Lab Med 62:2001\u20132010. https:\/\/doi.org\/10.1515\/cclm-2023-1472","journal-title":"Clin Chem Lab Med"},{"key":"2151_CR45","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.6430401","author":"D-L Maneca","year":"2022","unstructured":"Maneca D-L, Luo W, Krahn A, Del Cid PE, Shlaifer I, Nicouleau M et al (2022) Production of recombinant \u03b1 synuclein monomers and preformed fibrils (PFFs). Zenodo. https:\/\/doi.org\/10.5281\/zenodo.6430401"},{"key":"2151_CR46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11481-019-09835-4","volume":"14","author":"S Manne","year":"2019","unstructured":"Manne S, Kondru N, Hepker M, Jin H, Anantharam V, Lewis M et al (2019) Ultrasensitive detection of aggregated alpha-synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the RT-QuIC assay: new high-throughput neuroimmune biomarker assay for parkinsonian disorders. J Neuroimmune Pharmacol 14:423\u2013435. https:\/\/doi.org\/10.1007\/s11481-019-09835-4","journal-title":"J Neuroimmune Pharmacol"},{"key":"2151_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/mds.27907","volume":"35","author":"S Manne","year":"2020","unstructured":"Manne S, Kondru N, Jin H, Anantharam V, Huang X, Kanthasamy A et al (2020) Alpha-synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson\u2019s disease patients. Mov Disord 35:268\u2013278. https:\/\/doi.org\/10.1002\/mds.27907","journal-title":"Mov Disord"},{"key":"2151_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-022-00283-4","volume":"11","author":"I Martinez-Valbuena","year":"2022","unstructured":"Martinez-Valbuena I, Visanji NP, Kim A, Lau HHC, So RWL, Alshimemeri S et al (2022) Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy. Transl Neurodegener 11:7. https:\/\/doi.org\/10.1186\/s40035-022-00283-4","journal-title":"Transl Neurodegener"},{"key":"2151_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00401-025-02904-4","volume":"149","author":"A Mastrangelo","year":"2025","unstructured":"Mastrangelo A, Caldera S, Mastenbroek SE, Vittoriosi E, Janelidze S, Serrano GE et al (2025) Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants. Acta Neuropathol 149:67. https:\/\/doi.org\/10.1007\/s00401-025-02904-4","journal-title":"Acta Neuropathol"},{"key":"2151_CR50","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y et al (2023) Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 29:1448\u20131455. https:\/\/doi.org\/10.1038\/s41591-023-02358-9","journal-title":"Nat Med"},{"key":"2151_CR51","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1474-4422(25)00157-7","volume":"24","author":"CD Orru","year":"2025","unstructured":"Orru CD, Vaughan DP, Vijiaratnam N, Real R, Martinez-Carrasco A, Fumi R et al (2025) Diagnostic and prognostic value of alpha-synuclein seed amplification assay kinetic measures in Parkinson\u2019s disease: a longitudinal cohort study. Lancet Neurol 24:580\u2013590. https:\/\/doi.org\/10.1016\/S1474-4422(25)00157-7","journal-title":"Lancet Neurol"},{"key":"2151_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s44328-024-00023-w","volume":"2","author":"S Parveen","year":"2025","unstructured":"Parveen S, Alam P, Orru CD, Vascellari S, Hughson AG, Zou WQ et al (2025) A same day alpha-synuclein RT-QuIC seed amplification assay for synucleinopathy biospecimens. NPJ Biosens 2:8. https:\/\/doi.org\/10.1038\/s44328-024-00023-w","journal-title":"NPJ Biosens"},{"key":"2151_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-4939-2978-8_9","volume":"1345","author":"W Paslawski","year":"2016","unstructured":"Paslawski W, Lorenzen N, Otzen DE (2016) Formation and characterization of alpha-synuclein oligomers. Methods Mol Biol 1345:133\u2013150. https:\/\/doi.org\/10.1007\/978-1-4939-2978-8_9","journal-title":"Methods Mol Biol"},{"key":"2151_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab045","volume":"3","author":"D Perra","year":"2021","unstructured":"Perra D, Bongianni M, Novi G, Janes F, Bessi V, Capaldi S et al (2021) Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Commun 3:fcab045. https:\/\/doi.org\/10.1093\/braincomms\/fcab045","journal-title":"Brain Commun"},{"key":"2151_CR55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00249-023-01629-0","volume":"52","author":"JS Philo","year":"2023","unstructured":"Philo JS (2023) SEDNTERP: a calculation and database utility to aid interpretation of analytical ultracentrifugation and light scattering data. Eur Biophys J 52:233\u2013266. https:\/\/doi.org\/10.1007\/s00249-023-01629-0","journal-title":"Eur Biophys J"},{"key":"2151_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/biom11060820","author":"I Poggiolini","year":"2021","unstructured":"Poggiolini I, Erskine D, Vaikath NN, Ponraj J, Mansour S, Morris CM et al (2021) RT-QuIC using C-terminally truncated \u03b1-synuclein forms detects differences in seeding propensity of different brain regions from synucleinopathies. Biomolecules. https:\/\/doi.org\/10.3390\/biom11060820","journal-title":"Biomolecules"},{"key":"2151_CR57","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2022","unstructured":"Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A et al (2022) Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145:584\u2013595. https:\/\/doi.org\/10.1093\/brain\/awab431","journal-title":"Brain"},{"key":"2151_CR58","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1212\/WNL.0000000000012438","volume":"97","author":"M Rossi","year":"2021","unstructured":"Rossi M, Baiardi S, Teunissen CE, Quadalti C, van de Beek M, Mammana A et al (2021) Diagnostic value of the CSF \u03b1-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies. Neurology 97:e930\u2013e940. https:\/\/doi.org\/10.1212\/WNL.0000000000012438","journal-title":"Neurology"},{"key":"2151_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orru CD et al (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140:49\u201362. https:\/\/doi.org\/10.1007\/s00401-020-02160-8","journal-title":"Acta Neuropathol"},{"key":"2151_CR60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM et al (2021) High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol Commun 9:179. https:\/\/doi.org\/10.1186\/s40478-021-01282-8","journal-title":"Acta Neuropathol Commun"},{"key":"2151_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgae316","author":"A Saran","year":"2024","unstructured":"Saran A, Kim H-M, Manning I, Hancock MA, Schmitz C, Madej M et al (2024) Unveiling the molecular mechanisms of the type IX secretion system\u2019s response regulator: structural and functional insights. PNAS Nexus. https:\/\/doi.org\/10.1093\/pnasnexus\/pgae316","journal-title":"PNAS Nexus"},{"key":"2151_CR62","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0006-3495(02)75469-6","volume":"82","author":"P Schuck","year":"2002","unstructured":"Schuck P, Perugini MA, Gonzales NR, Howlett GJ, Schubert D (2002) Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys J 82:1096\u20131111. https:\/\/doi.org\/10.1016\/S0006-3495(02)75469-6","journal-title":"Biophys J"},{"key":"2151_CR63","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","volume":"585","author":"M Schweighauser","year":"2020","unstructured":"Schweighauser M, Shi Y, Tarutani A, Kametani F, Murzin AG, Ghetti B et al (2020) Structures of alpha-synuclein filaments from multiple system atrophy. Nature 585:464\u2013469. https:\/\/doi.org\/10.1038\/s41586-020-2317-6","journal-title":"Nature"},{"key":"2151_CR64","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X et al (2020) Discriminating alpha-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578:273\u2013277. https:\/\/doi.org\/10.1038\/s41586-020-1984-7","journal-title":"Nature"},{"key":"2151_CR65","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C et al (2017) Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 74:163\u2013172. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4547","journal-title":"JAMA Neurol"},{"key":"2151_CR66","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M et al (2024) A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol 23:178\u2013190. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2","journal-title":"Lancet Neurol"},{"key":"2151_CR67","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1021\/cn3001203","volume":"4","author":"PK Singh","year":"2013","unstructured":"Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK (2013) Curcumin modulates alpha-synuclein aggregation and toxicity. ACS Chem Neurosci 4:393\u2013407. https:\/\/doi.org\/10.1021\/cn3001203","journal-title":"ACS Chem Neurosci"},{"key":"2151_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168011","volume":"435","author":"RWL So","year":"2023","unstructured":"So RWL, Watts JC (2023) Alpha-synuclein conformational strains as drivers of phenotypic heterogeneity in neurodegenerative diseases. J Mol Biol 435:168011. https:\/\/doi.org\/10.1016\/j.jmb.2023.168011","journal-title":"J Mol Biol"},{"key":"2151_CR69","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00401-021-02288-1","volume":"141","author":"A Sokratian","year":"2021","unstructured":"Sokratian A, Ziaee J, Kelly K, Chang A, Bryant N, Wang S et al (2021) Heterogeneity in alpha-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia. Acta Neuropathol 141:547\u2013564. https:\/\/doi.org\/10.1007\/s00401-021-02288-1","journal-title":"Acta Neuropathol"},{"key":"2151_CR70","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.tibtech.2024.01.007","volume":"42","author":"C Soto","year":"2024","unstructured":"Soto C (2024) Alpha-Synuclein seed amplification technology for Parkinson\u2019s disease and related synucleinopathies. Trends Biotechnol 42:829\u2013841. https:\/\/doi.org\/10.1016\/j.tibtech.2024.01.007","journal-title":"Trends Biotechnol"},{"key":"2151_CR71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1749-6632.2000.tb06900.x","volume":"920","author":"MG Spillantini","year":"2000","unstructured":"Spillantini MG, Goedert M (2000) The alpha-synucleinopathies: Parkinson\u2019s disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 920:16\u201327. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb06900.x","journal-title":"Ann N Y Acad Sci"},{"key":"2151_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012554","volume":"20","author":"A Srivastava","year":"2024","unstructured":"Srivastava A, Wang Q, Orru CD, Fernandez M, Compta Y, Ghetti B et al (2024) Enhanced quantitation of pathological alpha-synuclein in patient biospecimens by RT-QuIC seed amplification assays. PLoS Pathog 20:e1012554. https:\/\/doi.org\/10.1371\/journal.ppat.1012554","journal-title":"PLoS Pathog"},{"key":"2151_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-022-03595-z","author":"HG Standke","year":"2022","unstructured":"Standke HG, Kraus A (2022) Seed amplification and RT-QuIC assays to investigate protein seed structures and strains. Cell Tissue Res. https:\/\/doi.org\/10.1007\/s00441-022-03595-z","journal-title":"Cell Tissue Res"},{"key":"2151_CR74","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00441-018-2814-1","volume":"373","author":"JA Steiner","year":"2018","unstructured":"Steiner JA, Quansah E, Brundin P (2018) The concept of alpha-synuclein as a prion-like protein: ten years after. Cell Tissue Res 373:161\u2013173. https:\/\/doi.org\/10.1007\/s00441-018-2814-1","journal-title":"Cell Tissue Res"},{"key":"2151_CR75","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1021\/acs.biochem.0c00725","volume":"59","author":"AD Stephens","year":"2020","unstructured":"Stephens AD, Matak-Vinkovic D, Fernandez-Villegas A, Kaminski Schierle GS (2020) Purification of recombinant alpha-synuclein: a comparison of commonly used protocols. Biochemistry 59:4563\u20134572. https:\/\/doi.org\/10.1021\/acs.biochem.0c00725","journal-title":"Biochemistry"},{"key":"2151_CR76","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0014-5793(02)02638-8","volume":"517","author":"VN Uversky","year":"2002","unstructured":"Uversky VN, Yamin G, Souillac PO, Goers J, Glaser CB, Fink AL (2002) Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett 517:239\u2013244. https:\/\/doi.org\/10.1016\/s0014-5793(02)02638-8","journal-title":"FEBS Lett"},{"key":"2151_CR77","doi-asserted-by":"publisher","first-page":"17797","DOI":"10.1073\/pnas.1113260108","volume":"108","author":"W Wang","year":"2011","unstructured":"Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LT, Liao J et al (2011) A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A 108:17797\u201317802. https:\/\/doi.org\/10.1073\/pnas.1113260108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2151_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.3311","volume":"78","author":"Z Wang","year":"2020","unstructured":"Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M et al (2020) Skin alpha-Synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol 78:1\u201311. https:\/\/doi.org\/10.1001\/jamaneurol.2020.3311","journal-title":"JAMA Neurol"},{"key":"2151_CR79","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-025-00469-6","volume":"14","author":"JA Wiseman","year":"2025","unstructured":"Wiseman JA, Turner CP, Faull RLM, Halliday GM, Dieriks BV (2025) Refining alpha-synuclein seed amplification assays to distinguish Parkinson\u2019s disease from multiple system atrophy. Transl Neurodegener 14:7. https:\/\/doi.org\/10.1186\/s40035-025-00469-6","journal-title":"Transl Neurodegener"},{"key":"2151_CR80","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.160696","volume":"4","author":"C Xue","year":"2017","unstructured":"Xue C, Lin TY, Chang D, Guo Z (2017) Thioflavin t as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R Soc Open Sci 4:160696. https:\/\/doi.org\/10.1098\/rsos.160696","journal-title":"R Soc Open Sci"},{"key":"2151_CR81","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","volume":"610","author":"Y Yang","year":"2022","unstructured":"Yang Y, Shi Y, Schweighauser M, Zhang X, Kotecha A, Murzin AG et al (2022) Structures of alpha-synuclein filaments from human brains with Lewy pathology. Nature 610:791\u2013795. https:\/\/doi.org\/10.1038\/s41586-022-05319-3","journal-title":"Nature"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02151-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02151-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02151-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:36:55Z","timestamp":1762346215000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-02151-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02151-4","relation":{"references":[{"id-type":"doi","id":"10.5281\/zenodo.6430401","asserted-by":"subject"}]},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human \u03b1-synucleinopathy samples were provided by the Massachusetts Alzheimer\u2019s Disease Research Center. Informed consent was obtained either by the patient prior to death or by family member prior to or at the time of death. The use of human tissue was in accordance with guidelines provided by the University of Toronto under an approved human participant ethics protocol (#38879; \u201cUse of human tissue for research on neurodegenerative diseases\u201d), and all relevant ethical regulations were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}